Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Comment by Viking2233on Jul 28, 2024 11:31am
88 Views
Post# 36151689

RE:The LSALT study currently has 9 locations

RE:The LSALT study currently has 9 locationsHi Pete, 

Where are the 9 locations? I am only aware of 5 locations in Turkey currently dosing?

We have 3 apparently coming in Canada with 1 location in Calgary and 2 locations in Toronto but they are not dosing nor do they have final approvals?

I think your posting is not accurate. Is there something you know that the rest of us dont?

You dont have to go overboard releasing old news after old news in rapid succession, it really does feel
yoy are being paid to do this. I sure hope you are not an employee of Arch or being paid by Arch as this board is a waste of time and money.

There are much better venues with target audiences in trade shows and investor conferences etc to promote tge Arch story.

Your posts certainly highlight the accomplishments and the science but this board is certainly not going to solve the issues of lack of buyers and lack of awareness coupled with lack of Institutional investors.
<< Previous
Bullboard Posts
Next >>